Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04498884
Other study ID # RIN30-70-CL
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 18, 2017
Est. completion date October 24, 2017

Study information

Verified date July 2020
Source Geropharm
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pharmacokinetics and pharmacodynamics study of 2 formulations of insulin mixtures Rinsulin® Mix 30/70, Suspension for Subcutaneous Administration, 100 IU / ml (OJSC GEROPHARM-Bio, Russia) versus Humulin® M3, Suspension for Subcutaneous Administration, 100 IU / ml (Lilly France, France).


Description:

Double-blinded, randomized, comparative, crossover study of comparative pharmacokinetics of Rinsulin® mix 30/70, suspension for subcutaneous administration, 100 IU / ml (OJSC GEROPHARM-Bio, Russia) and Humulin® M3, suspension for subcutaneous administration, 100 IU / ml (Lilly France, France) using hyperinsulinemic euglycemic clamp method on healthy volunteers.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date October 24, 2017
Est. primary completion date October 24, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Signed informed consent to participate in the study.

- Men of the Caucasian race with a verified diagnosis "healthy" according to the data of standard clinical, laboratory and instrumental examination methods.

- Age 18-50, inclusive.

- Body mass index 18.5 - 27 kg / m2.

- Volunteers who have sexual contact with fertile women should agree to use barrier methods of contraception while participating in the study (unless they have undergone surgical sterilization). Study Participants must also not become a sperm donor within the specified period.

- Consent to all restrictions imposed during the study.

Exclusion Criteria:

- Acute inflammatory diseases within 3 weeks from the moment of complete recovery to the stage of screening.

- Presence in the family history of the closest relatives cases of verified diagnosis of diabetes mellitus of any type.

- Deviations from the norm of basic vital indicators (heart rate, blood pressure, respiratory rate, body temperature) and ECG from normal values and laboratory values from reference values during screening.

- Fasting plasma glucose> 6.1 mmol / L at screening.

- HbA1C> 6% at the time of screening.

- Oral glucose tolerance test - blood glucose level =7.8 mmol / L (2 hours after glucose loading) during screening.

- Hard-to-reach veins of the upper extremities, vein thrombosis, history of thrombophlebitis or family history of close relatives, "compromised" veins due to frequent preceding venipuncture.

- Taking medications, phytopreparations, biologically active additives within 14 days before screening.

- Significant blood loss 3 months before screening due to, for example, but not limited to the following points: a. donor blood donation; b. extended surgery or trauma leading to significant blood loss.

- Incomplete recovery from surgery or surgery scheduled while the volunteer is participating in the study.

- Mental, physical and other reasons interferes with adequately assessing behavior and correctly fulfill the conditions of the research protocol incl.:

1. A history of mental illness;

2. Current or history (three years before the first administration of the study drug) of narcotic, drug and / or substance abuse. A positive test for the content of drugs in urine during the screening period;

3. Anamnestic information about alcoholism or intake of more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of dry wine or 50 ml of spirits). A positive test for alcohol in breath during the screening period;

4. Nicotine addiction (regular use of tobacco less than 6 months before screening).

- Any chronic diseases, incl. but not limited to positive test results for hepatitis C or hepatitis B, HIV, syphilis at the time of screening, Burdened allergological history.

- Presence of suspicion of an inflammatory disease of the urinary system based on the results of urinalysis during screening.

- Presence of oncological diseases within 5 years before the screening.

- History of organ transplantation (except of corneal transplant performed more than 3 months before the first injection of the study drug).

- Participation in a clinical trial of any drug or experimental medical device within 3 months prior to the first administration of the study drug.

- Any other condition that, in the reasonable opinion of the research physician, makes it difficult for the volunteer to participate in the study.

- History of hypersensitivity to heparin, insulin or any of the excipients of the investigational drugs.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rinsulin® mix 30/70
one subcutaneous injection at a dose of 0.4 IU/kg
Humulin® M3
one subcutaneous injection at a dose of 0.4 IU/kg

Locations

Country Name City State
Russian Federation "National Medical Research Center of Endocrinology" of the Ministry of Health of the Russian Federation Moscow
Russian Federation National Medical Research Center in name of V.A. Almazov " of the Ministry of Health of the Russian Federation Saint-Petersburg
Russian Federation LLC "BioEk", Russian Federation St. Petersburg

Sponsors (1)

Lead Sponsor Collaborator
Geropharm

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUC 0-12 Total area under the curve "drug concentration - time" in the time interval from 0 to 12 h -0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Primary Cmax Test Drug Observed Maximum Plasma Concentration -0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Primary GIR 0-12 Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 12 h 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
Primary GIR 0-24 Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 24 h 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
Primary GIR max Maximum glucose infusion rate over the study period 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
Primary tGIRmax Time to reach maximum glucose infusion rate 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
Primary TGIRlag Time between the drug administration and the onset of action 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
Secondary AUC 0-2 Total area under the curve "drug concentration - time" in the time interval from 0 to 2 h -0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary AUC 0-24 Total area under the curve "drug concentration - time" in the time interval from 0 to 24 h -0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary AUC 0-6 Total area under the curve "drug concentration - time" in the time interval from 0 to 6 h -0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary AUC 0-8 Total area under the curve "drug concentration - time" in the time interval from 0 h to 8 -0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary mean residence time average residence time of a drug molecule in the body -0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary kel constant for drug elimination rate -0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary Tmax Time to reach test drug Maximum Plasma Concentration -0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary t1/2 Half-life of a drug tested -0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary t50%-early reaching 50% of the maximum insulin concentration before reaching Cmax -0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary t50%-late reaching 50% of the maximum insulin concentration after reaching Cmax -0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
Secondary ratio ?max/AUC0-t relative absorption rate -0.5 , 0, every 15 min till 6 h, every 30 min till 11h, every 60 min till 17h, every 120 min till 24h
See also
  Status Clinical Trial Phase
Completed NCT03705533 - Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State Phase 1
Completed NCT04938856 - Bioequivalence of Lamnet (Lamotrigine)100mg Tablet With the Reference Product Lamictal 100mg (Lamotrigine) Tablet Under Fasting Conditions Phase 1
Completed NCT03646331 - Bioequivalence of Imeglimin Tablet Formulations Phase 1
Completed NCT04564456 - A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers Phase 1
Completed NCT05197517 - Bioequivalence Study of Rosuvastatin in Healthy Volunteers Under Fasting Condition Phase 1
Completed NCT03702894 - Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions Phase 1
Withdrawn NCT02894515 - Bioequivalence Study of Idalopirdine in Healthy Subjects Phase 1
Completed NCT03018015 - Ibuprofen Bioavailability Trial With Oral Single Dose Administration. Phase 1
Completed NCT02206295 - Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg Phase 1
Completed NCT01331993 - A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation Phase 1
Completed NCT01260805 - A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers. Phase 1
Recruiting NCT06066112 - Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body Phase 1
Completed NCT05477810 - Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets in Healthy Adults Under Fasting Conditions Early Phase 1
Completed NCT04546256 - A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers Phase 1
Completed NCT05083325 - Bioavailability of Oseltamivir Phosphate 75 mg With Regards to Reference Product Phase 1
Completed NCT05061901 - Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions Phase 1
Recruiting NCT04138888 - A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions Phase 1
Completed NCT05145621 - Oral Bio-equivalence Study Phase 1
Completed NCT06124560 - Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions. Phase 1
Completed NCT03340753 - Bioavailability of KBP-5074 Tablet vs Capsule Formulations Phase 1